Molecular Health Launches Expanded Platform Strategy for Engineus™ Healthcare Decision Engine

BOSTON and HEIDELBERG, Germany, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Molecular Health today announced an expanded strategy for its novel Engineus™ technology platform to include a wide range of healthcare decision support products. Based on the most comprehensive biomedical data warehouse in the world, Engineus™ now offers highly-scalable precision medicine applications across the major healthcare categories: diagnostics, clinical decision support, therapeutics discovery and development.

Engineus™ is a global, unique, and integrated biomedical reference knowledge system that provides healthcare professionals the decision support capabilities they need to optimally leverage the opportunities of big data in healthcare. Engineus™ is expert-curated, quality-controlled, and constantly growing and being refined to make it optimally positioned to improve the efficiency of global healthcare, as the broadest of any data-driven platforms available today.

Engineus™ provides clinicians, lab partners and pharmaceutical companies the ability to make precise and individualized evidence-based diagnostic, clinical and therapeutic decisions by combining biomedical reference knowledge with best-in-breed analytics, data display and reporting.

Engineus™ is powered by data from 24 million scientific and medical publications, 76,000 drug-to-drug interactions, 6,000 biomarker facts for drug efficacy and safety, 85,000 gene variants, 40,000 drugs, 109,000 clinical trials, 270,000 protein interactions and 7 million patient medical records for drug safety among other data.

“Big data is changing the way healthcare is practiced today and further evolving the adoption of precision medicine,” said Lutz Voelker, CEO of Molecular Health. “The market need to improve healthcare efficiency grows exponentially every day. With our Engineus™ platform, we are uniquely positioned to interpret and analyze this data for actionable healthcare decisions across clinical decisions, diagnostics, therapeutics discovery and development.”

Mr. Voelker continued, “In order to achieve this level of interpretation, our decision engine leverages the full spectrum of available data – including molecular and end-to-end NGS testing, chemical, lab diagnostics and electronic medical records data. This enables Engineus™ to improve therapeutic efficacy, deepen safety research, optimize clinical trials, and enable new biomarker discoveries.”

To meet the growing needs of the global healthcare industry for evidence-based treatment decisions, Molecular Health plans to further expand the breadth of its platform beyond cancer, continuously adding new data types, diagnostic technologies and other disease entities and therapies, for example: metabolic diseases, cardiovascular diseases and immunotherapy.

About Molecular Health

Molecular Health GmbH is headquartered in Heidelberg, Germany and has the first registered medical device of its kind for personalized cancer medicine in Europe. In the United States, Molecular Health Inc., headquartered in Boston, Massachusetts, with a laboratory and support center in Greater Houston, Texas, is a wholly owned subsidiary of Molecular Health GmbH. To learn more, please visit:

Media Contacts U.S.: Mark Rodgers +1 832-247-3068 EMEA: Carla Mertens +49 6221 43851-2275

Source:Molecular Health